Clinical Trial Update: A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing how long the immune response lasts and the immune response after a booster dose of the MenACWY meningococcal vaccine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease
• Meningococcal Meningitis

Drugs mentioned

• Menveo (meningococcal group A, C, W-135 and Y conjugate vaccine)

Snippet

Sponsor: Novartis Vaccines | Conditions: Meningococcal Disease, Meningococcal Meningitis | Phase 2 | Status: COMPLETED | Results posted: 2011-09-13